Gilead Sciences Inc. (GILD) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, GILD scores 82 out of 100 with a letter grade of A- and a verdict label of "Roarable Buy — Superior Risk/Reward." The five pillars are:

• Fundamental Cash Engine (15 / 20): Per the RQD rating, ROIC is 21% and FCF yield is 4.6%. This pillar is solid but is the lowest-scoring of the five, indicating that cash generation relative to the valuation is a comparatively weaker leg of the thesis than other factors.
• Whale 13F Flow (19 / 20): The rating describes institutional accumulation and options positioning as a strength. This is the highest-scoring pillar. Note that the holders section of the source data is empty, so the underlying 13F detail cannot be verified in this dossier.
• Insider Conviction (16 / 20): The rating cites SEC Form 4 and Congressional PTR cluster flow as supportive. Underlying transaction records are not provided in the source data.
• Macro Regime Fit (14 / 20): Per the RQD rating, beta is 0.88 and sector sensitivity is a factor. A beta below 1.0 implies, per the rating's framing, lower sensitivity to broad market moves than the overall market.
• Forensic Balance Sheet (18 / 20): Per the RQD rating, Altman Z is 5.87, Piotroski F is 8 out of 9, and Debt/Equity is 0.97. This is the second-highest pillar and supports the view of a financially sound balance sheet.

For a prospective investor, the investment implications drawn from these pillars are as follows. The upside drivers are the institutional flow and balance-sheet strength. The valuation tradeoff is that the stock trades at a trailing P/E of 24.1 and an EV/EBITDA of 21 per the market data, which are not low absolute multiples, so the thesis leans on the quality and durability of earnings rather than on cheapness. The FCF yield of 4.6% is the pillar with the most room for scrutiny. This analysis is educational and is not personalized financial advice.

Gilead Sciences Inc. (GILD) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company carries a market capitalization of $205.3B. Per the market data, its gross margin is 78.8%, operating margin is 34%, and net margin is 28.9%. The source data does not describe its specific products, customers, or revenue model beyond these classifications.

Per the SEC financials, revenue rose across the three reported periods, from $27116.0M in FY 2023 to $29443.0M in FY 2025. Net income moved from $5665.0M to $480.0M in FY 2024 and then to $8510.0M in FY 2025, and operating income followed a similar path. Per the Roarable RQD rating, ROIC is 21%, the Altman Z-Score is 5.87, and the Piotroski F-Score is 8 out of 9. Per the same rating, Debt/Equity is 0.97, and debt was reported at $22129.0M in FY 2025, down from $26428.4M in FY 2023.

Per the recent news feed, five items are listed for GILD:

• A Yahoo Finance report describing a stock decline despite market gains, flagged GREEN as a CATALYST.
• A Trefis report on the company's cash yield, flagged YELLOW as MARKET WIRE.
• An Investor's Business Daily report stating the company hit a record and posted its best sales growth in a decade, flagged GREEN as a CATALYST.
• A Motley Fool buying guide, flagged YELLOW as MARKET WIRE.
• An Investing.com report that BofA raised its price target on growth outlook, flagged GREEN as a CATALYST.
• A Yahoo Finance piece on whether the stock can keep rising in 2027, flagged YELLOW as MARKET WIRE.

The green-flagged items are the catalyst-type reports and the yellow-flagged items are general market commentary. The headlines are the only content available; the underlying articles are not included in the source data. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be established from the source data.

• What are the company's specific products and revenue drivers, given that the source data provides only sector and industry classifications?
• Why are EPS and cash balances marked N/A across all reported periods, and how do those figures reconcile with net income and FCF?
• What explains the swing in net income from $5665.0M in FY 2023 to $480.0M in FY 2024 before recovering to $8510.0M in FY 2025?
• What are the consensus rating and price targets, given that the analyst data is empty?
• What is the identity and size of the institutional and insider holders behind the whale and insider pillar scores?